GAD 铝佐剂免疫疗法治疗 1 型糖尿病。

GAD-alum immunotherapy in Type 1 diabetes mellitus.

机构信息

Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR 72202, USA.

出版信息

Immunotherapy. 2011 Mar;3(3):323-32. doi: 10.2217/imt.11.9.

DOI:10.2217/imt.11.9

Abstract

Glutamic acid decarboxylase (GAD)-alum (Diamyd(®), Diamyd Medical, Stockholm, Sweden) is an adjuvant-formulated vaccine incorporating recombinant human GAD65, the specific isoform of GAD expressed in human pancreatic β-cells and a major antigen targeted by autoreactive T lymphocytes in Type 1 diabetes mellitus. Intermittent vaccination with this protein is theorized to induce immune tolerance to GAD65, thereby potentially interrupting further β-cell destruction. Hence, clinical trials are ongoing to examine the efficacy and safety of GAD-alum immunotherapy in patients with autoimmune-mediated forms of diabetes, including Type 1 diabetes and latent autoimmune diabetes in adults.

摘要

谷氨酸脱羧酶 (GAD)-铝佐剂（Diamyd(®)，Diamyd Medical，斯德哥尔摩，瑞典）是一种包含重组人 GAD65 的佐剂配方疫苗，GAD65 是人胰腺β细胞中表达的特定 GAD 同工型，也是 1 型糖尿病中自身反应性 T 淋巴细胞靶向的主要抗原。间歇性接种这种蛋白被认为可以诱导针对 GAD65 的免疫耐受，从而有可能阻止进一步的β细胞破坏。因此，正在进行临床试验以检查 GAD-铝佐剂免疫疗法在自身免疫介导的糖尿病患者中的疗效和安全性，包括 1 型糖尿病和成人隐匿性自身免疫性糖尿病。